ArticleClinical & experimental metastasis2026
Magnetic resonance-guided stereotactic body radiotherapy (MRIgSBRT) for nodal disease in oligometastatic setting: a single-institution study.
Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the feasibility and clinical outcomes of MRIgSBRT for nodal recurrence in the oligometastatic disease (OMD) setting, focusing on per-lesion outcomes and prognostic factors. We collected clinical and dosimetric data from a retrospective single-center cohort of patients treated with a 0.35 T MRIgSBRT for nodal recurrences. Endpoints included the 1-year progression-free survival (PFS), local progression-free survival (LPFS), and 3-year overall survival (OS) rate from recurrence. Per-lesion Kaplan-Meier and Cox regression assessed clinical, dosimetric, and technical predictors. 71 patients received nodal MRIgSBRT, with a total of 115 treated metastatic lesions. Local control was high: LPFS 95.5% at 12 months and 94.0% at 24/36 months. OS was favorable (100% at 12 months, 97.2% at 24 months, 95.3% at 36 months). Systemic progression drove most events: PFS 52.6% at 12 months and 24.4% at 24 months; median 12.4 months. No clinically relevant acute or late toxicity was observed. On multivariable analysis, BED
Indexed as
Identifiers
42036517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.